nodes	percent_of_prediction	percent_of_DWPC	metapath
Apomorphine—HTR2A—phrenic nerve—lung cancer	0.0161	0.386	CbGeAlD
Apomorphine—HTR2A—pulmonary artery—lung cancer	0.00585	0.14	CbGeAlD
Apomorphine—CALY—lymph node—lung cancer	0.00237	0.0568	CbGeAlD
Apomorphine—ADRA1D—epithelium—lung cancer	0.00221	0.053	CbGeAlD
Apomorphine—Sweating increased—Paclitaxel—lung cancer	0.00189	0.00338	CcSEcCtD
Apomorphine—Nausea—Gefitinib—lung cancer	0.00189	0.00337	CcSEcCtD
Apomorphine—Shock—Erlotinib—lung cancer	0.00187	0.00334	CcSEcCtD
Apomorphine—Asthenia—Teniposide—lung cancer	0.00186	0.00332	CcSEcCtD
Apomorphine—Hyperhidrosis—Topotecan—lung cancer	0.00186	0.00331	CcSEcCtD
Apomorphine—Pruritus—Teniposide—lung cancer	0.00183	0.00327	CcSEcCtD
Apomorphine—Pneumonia—Etoposide—lung cancer	0.00178	0.00317	CcSEcCtD
Apomorphine—Diarrhoea—Teniposide—lung cancer	0.00177	0.00317	CcSEcCtD
Apomorphine—Dehydration—Docetaxel—lung cancer	0.00177	0.00316	CcSEcCtD
Apomorphine—Flushing—Irinotecan—lung cancer	0.00177	0.00316	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Topotecan—lung cancer	0.00175	0.00312	CcSEcCtD
Apomorphine—Dyskinesia—Doxorubicin—lung cancer	0.00174	0.00311	CcSEcCtD
Apomorphine—Pneumonia—Paclitaxel—lung cancer	0.00174	0.00311	CcSEcCtD
Apomorphine—Orthostatic hypotension—Docetaxel—lung cancer	0.00174	0.00311	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Erlotinib—lung cancer	0.00173	0.00309	CcSEcCtD
Apomorphine—Insomnia—Erlotinib—lung cancer	0.00172	0.00307	CcSEcCtD
Apomorphine—Chest pain—Vinorelbine—lung cancer	0.00171	0.00306	CcSEcCtD
Apomorphine—Arthralgia—Vinorelbine—lung cancer	0.00171	0.00306	CcSEcCtD
Apomorphine—Dyspnoea—Topotecan—lung cancer	0.00171	0.00306	CcSEcCtD
Apomorphine—Ecchymosis—Methotrexate—lung cancer	0.00171	0.00305	CcSEcCtD
Apomorphine—Nasopharyngitis—Docetaxel—lung cancer	0.0017	0.00304	CcSEcCtD
Apomorphine—Dyspnoea—Erlotinib—lung cancer	0.00169	0.00302	CcSEcCtD
Apomorphine—Constipation—Vinblastine—lung cancer	0.00169	0.00302	CcSEcCtD
Apomorphine—Urinary tract infection—Paclitaxel—lung cancer	0.00168	0.00301	CcSEcCtD
Apomorphine—Fatigue—Topotecan—lung cancer	0.00165	0.00296	CcSEcCtD
Apomorphine—Vomiting—Teniposide—lung cancer	0.00165	0.00294	CcSEcCtD
Apomorphine—Constipation—Topotecan—lung cancer	0.00164	0.00293	CcSEcCtD
Apomorphine—Fatigue—Erlotinib—lung cancer	0.00164	0.00292	CcSEcCtD
Apomorphine—Feeling abnormal—Vinblastine—lung cancer	0.00163	0.00291	CcSEcCtD
Apomorphine—Injection site reaction—Doxorubicin—lung cancer	0.00163	0.00291	CcSEcCtD
Apomorphine—Constipation—Erlotinib—lung cancer	0.00162	0.0029	CcSEcCtD
Apomorphine—Headache—Teniposide—lung cancer	0.00162	0.0029	CcSEcCtD
Apomorphine—Flushing—Cisplatin—lung cancer	0.00161	0.00287	CcSEcCtD
Apomorphine—Back pain—Irinotecan—lung cancer	0.0016	0.00287	CcSEcCtD
Apomorphine—Angina pectoris—Docetaxel—lung cancer	0.0016	0.00286	CcSEcCtD
Apomorphine—Feeling abnormal—Topotecan—lung cancer	0.00158	0.00283	CcSEcCtD
Apomorphine—Back pain—Gemcitabine—lung cancer	0.00156	0.00279	CcSEcCtD
Apomorphine—Nausea—Teniposide—lung cancer	0.00154	0.00275	CcSEcCtD
Apomorphine—Hypotension—Vinorelbine—lung cancer	0.00153	0.00274	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Vinorelbine—lung cancer	0.0015	0.00267	CcSEcCtD
Apomorphine—DRD2—respiratory system—lung cancer	0.00149	0.0357	CbGeAlD
Apomorphine—Syncope—Irinotecan—lung cancer	0.00149	0.00266	CcSEcCtD
Apomorphine—Ecchymosis—Doxorubicin—lung cancer	0.00148	0.00264	CcSEcCtD
Apomorphine—Pneumonia—Docetaxel—lung cancer	0.00148	0.00264	CcSEcCtD
Apomorphine—Flushing—Etoposide—lung cancer	0.00147	0.00263	CcSEcCtD
Apomorphine—Dyspnoea—Vinorelbine—lung cancer	0.00146	0.00261	CcSEcCtD
Apomorphine—Loss of consciousness—Irinotecan—lung cancer	0.00146	0.00261	CcSEcCtD
Apomorphine—Flushing—Paclitaxel—lung cancer	0.00144	0.00258	CcSEcCtD
Apomorphine—Asthenia—Vinblastine—lung cancer	0.00142	0.00253	CcSEcCtD
Apomorphine—Fatigue—Vinorelbine—lung cancer	0.00142	0.00253	CcSEcCtD
Apomorphine—Constipation—Vinorelbine—lung cancer	0.0014	0.00251	CcSEcCtD
Apomorphine—Asthenia—Topotecan—lung cancer	0.00138	0.00246	CcSEcCtD
Apomorphine—Chest pain—Gemcitabine—lung cancer	0.00138	0.00246	CcSEcCtD
Apomorphine—Arthralgia—Gemcitabine—lung cancer	0.00138	0.00246	CcSEcCtD
Apomorphine—Confusional state—Irinotecan—lung cancer	0.00137	0.00244	CcSEcCtD
Apomorphine—Asthenia—Erlotinib—lung cancer	0.00136	0.00243	CcSEcCtD
Apomorphine—Mental disorder—Paclitaxel—lung cancer	0.00136	0.00243	CcSEcCtD
Apomorphine—Pruritus—Topotecan—lung cancer	0.00136	0.00243	CcSEcCtD
Apomorphine—Oedema—Irinotecan—lung cancer	0.00135	0.00242	CcSEcCtD
Apomorphine—Feeling abnormal—Vinorelbine—lung cancer	0.00135	0.00242	CcSEcCtD
Apomorphine—Diarrhoea—Vinblastine—lung cancer	0.00135	0.00241	CcSEcCtD
Apomorphine—Pruritus—Erlotinib—lung cancer	0.00134	0.0024	CcSEcCtD
Apomorphine—Back pain—Etoposide—lung cancer	0.00133	0.00238	CcSEcCtD
Apomorphine—Shock—Irinotecan—lung cancer	0.00133	0.00238	CcSEcCtD
Apomorphine—Oedema—Gemcitabine—lung cancer	0.00132	0.00236	CcSEcCtD
Apomorphine—Diarrhoea—Topotecan—lung cancer	0.00131	0.00235	CcSEcCtD
Apomorphine—Cardiac failure congestive—Doxorubicin—lung cancer	0.00131	0.00234	CcSEcCtD
Apomorphine—Hyperhidrosis—Irinotecan—lung cancer	0.00131	0.00234	CcSEcCtD
Apomorphine—Back pain—Paclitaxel—lung cancer	0.00131	0.00234	CcSEcCtD
Apomorphine—Dizziness—Vinblastine—lung cancer	0.00131	0.00233	CcSEcCtD
Apomorphine—Diarrhoea—Erlotinib—lung cancer	0.0013	0.00232	CcSEcCtD
Apomorphine—Anxiety—Cisplatin—lung cancer	0.00128	0.00228	CcSEcCtD
Apomorphine—Hyperhidrosis—Gemcitabine—lung cancer	0.00128	0.00228	CcSEcCtD
Apomorphine—Dizziness—Topotecan—lung cancer	0.00127	0.00227	CcSEcCtD
Apomorphine—Hypotension—Irinotecan—lung cancer	0.00127	0.00226	CcSEcCtD
Apomorphine—Vomiting—Vinblastine—lung cancer	0.00126	0.00224	CcSEcCtD
Apomorphine—Dizziness—Erlotinib—lung cancer	0.00126	0.00224	CcSEcCtD
Apomorphine—Headache—Vinblastine—lung cancer	0.00124	0.00221	CcSEcCtD
Apomorphine—Hypotension—Gemcitabine—lung cancer	0.00123	0.0022	CcSEcCtD
Apomorphine—Oedema—Cisplatin—lung cancer	0.00123	0.0022	CcSEcCtD
Apomorphine—Insomnia—Irinotecan—lung cancer	0.00122	0.00219	CcSEcCtD
Apomorphine—Flushing—Docetaxel—lung cancer	0.00122	0.00218	CcSEcCtD
Apomorphine—Vomiting—Topotecan—lung cancer	0.00122	0.00218	CcSEcCtD
Apomorphine—Syncope—Paclitaxel—lung cancer	0.00121	0.00217	CcSEcCtD
Apomorphine—Loss of consciousness—Etoposide—lung cancer	0.00121	0.00217	CcSEcCtD
Apomorphine—Vomiting—Erlotinib—lung cancer	0.00121	0.00216	CcSEcCtD
Apomorphine—Dyspnoea—Irinotecan—lung cancer	0.00121	0.00216	CcSEcCtD
Apomorphine—Somnolence—Irinotecan—lung cancer	0.0012	0.00215	CcSEcCtD
Apomorphine—Headache—Topotecan—lung cancer	0.0012	0.00215	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Gemcitabine—lung cancer	0.0012	0.00215	CcSEcCtD
Apomorphine—Insomnia—Gemcitabine—lung cancer	0.00119	0.00213	CcSEcCtD
Apomorphine—ADRA2C—bronchus—lung cancer	0.00119	0.0286	CbGeAlD
Apomorphine—Headache—Erlotinib—lung cancer	0.00119	0.00213	CcSEcCtD
Apomorphine—Loss of consciousness—Paclitaxel—lung cancer	0.00119	0.00212	CcSEcCtD
Apomorphine—Pain in extremity—Doxorubicin—lung cancer	0.00119	0.00212	CcSEcCtD
Apomorphine—Hyperhidrosis—Cisplatin—lung cancer	0.00119	0.00212	CcSEcCtD
Apomorphine—Asthenia—Vinorelbine—lung cancer	0.00118	0.0021	CcSEcCtD
Apomorphine—Dyspnoea—Gemcitabine—lung cancer	0.00118	0.0021	CcSEcCtD
Apomorphine—Chest pain—Etoposide—lung cancer	0.00117	0.0021	CcSEcCtD
Apomorphine—Nausea—Vinblastine—lung cancer	0.00117	0.0021	CcSEcCtD
Apomorphine—Somnolence—Gemcitabine—lung cancer	0.00117	0.00209	CcSEcCtD
Apomorphine—Fatigue—Irinotecan—lung cancer	0.00117	0.00209	CcSEcCtD
Apomorphine—Pruritus—Vinorelbine—lung cancer	0.00116	0.00208	CcSEcCtD
Apomorphine—Constipation—Irinotecan—lung cancer	0.00116	0.00207	CcSEcCtD
Apomorphine—Mental disorder—Docetaxel—lung cancer	0.00115	0.00206	CcSEcCtD
Apomorphine—Arthralgia—Paclitaxel—lung cancer	0.00115	0.00206	CcSEcCtD
Apomorphine—Chest pain—Paclitaxel—lung cancer	0.00115	0.00206	CcSEcCtD
Apomorphine—Hypotension—Cisplatin—lung cancer	0.00115	0.00205	CcSEcCtD
Apomorphine—Anxiety—Paclitaxel—lung cancer	0.00115	0.00205	CcSEcCtD
Apomorphine—Nausea—Topotecan—lung cancer	0.00114	0.00204	CcSEcCtD
Apomorphine—Fatigue—Gemcitabine—lung cancer	0.00114	0.00203	CcSEcCtD
Apomorphine—Confusional state—Etoposide—lung cancer	0.00114	0.00203	CcSEcCtD
Apomorphine—Constipation—Gemcitabine—lung cancer	0.00113	0.00201	CcSEcCtD
Apomorphine—Nausea—Erlotinib—lung cancer	0.00113	0.00201	CcSEcCtD
Apomorphine—Diarrhoea—Vinorelbine—lung cancer	0.00112	0.00201	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Cisplatin—lung cancer	0.00112	0.002	CcSEcCtD
Apomorphine—Feeling abnormal—Irinotecan—lung cancer	0.00112	0.00199	CcSEcCtD
Apomorphine—Confusional state—Paclitaxel—lung cancer	0.00111	0.00199	CcSEcCtD
Apomorphine—Back pain—Docetaxel—lung cancer	0.00111	0.00198	CcSEcCtD
Apomorphine—Dehydration—Doxorubicin—lung cancer	0.00111	0.00197	CcSEcCtD
Apomorphine—Oedema—Paclitaxel—lung cancer	0.0011	0.00197	CcSEcCtD
Apomorphine—Dyspnoea—Cisplatin—lung cancer	0.0011	0.00196	CcSEcCtD
Apomorphine—Hyperhidrosis—Etoposide—lung cancer	0.00109	0.00195	CcSEcCtD
Apomorphine—Feeling abnormal—Gemcitabine—lung cancer	0.00109	0.00194	CcSEcCtD
Apomorphine—Shock—Paclitaxel—lung cancer	0.00109	0.00194	CcSEcCtD
Apomorphine—Dizziness—Vinorelbine—lung cancer	0.00109	0.00194	CcSEcCtD
Apomorphine—Orthostatic hypotension—Doxorubicin—lung cancer	0.00109	0.00194	CcSEcCtD
Apomorphine—ADRA2C—trachea—lung cancer	0.00107	0.0257	CbGeAlD
Apomorphine—Hyperhidrosis—Paclitaxel—lung cancer	0.00107	0.00191	CcSEcCtD
Apomorphine—Pneumonia—Methotrexate—lung cancer	0.00106	0.0019	CcSEcCtD
Apomorphine—Nasopharyngitis—Doxorubicin—lung cancer	0.00106	0.0019	CcSEcCtD
Apomorphine—Drowsiness—Methotrexate—lung cancer	0.00106	0.00189	CcSEcCtD
Apomorphine—Hypotension—Etoposide—lung cancer	0.00105	0.00188	CcSEcCtD
Apomorphine—Vomiting—Vinorelbine—lung cancer	0.00104	0.00186	CcSEcCtD
Apomorphine—Hypotension—Paclitaxel—lung cancer	0.00103	0.00184	CcSEcCtD
Apomorphine—Headache—Vinorelbine—lung cancer	0.00103	0.00184	CcSEcCtD
Apomorphine—Syncope—Docetaxel—lung cancer	0.00103	0.00184	CcSEcCtD
Apomorphine—Feeling abnormal—Cisplatin—lung cancer	0.00101	0.00181	CcSEcCtD
Apomorphine—Loss of consciousness—Docetaxel—lung cancer	0.00101	0.0018	CcSEcCtD
Apomorphine—ADRA2C—cardiac atrium—lung cancer	0.00101	0.0241	CbGeAlD
Apomorphine—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.00101	0.0018	CcSEcCtD
Apomorphine—Dyspnoea—Etoposide—lung cancer	0.001	0.00179	CcSEcCtD
Apomorphine—Somnolence—Etoposide—lung cancer	0.001	0.00179	CcSEcCtD
Apomorphine—Angina pectoris—Doxorubicin—lung cancer	0.001	0.00179	CcSEcCtD
Apomorphine—Insomnia—Paclitaxel—lung cancer	0.000999	0.00178	CcSEcCtD
Apomorphine—Dyspnoea—Paclitaxel—lung cancer	0.000985	0.00176	CcSEcCtD
Apomorphine—HTR2A—respiratory system—lung cancer	0.000983	0.0236	CbGeAlD
Apomorphine—Somnolence—Paclitaxel—lung cancer	0.000982	0.00175	CcSEcCtD
Apomorphine—HTR2B—lung—lung cancer	0.000978	0.0234	CbGeAlD
Apomorphine—Chest pain—Docetaxel—lung cancer	0.000976	0.00174	CcSEcCtD
Apomorphine—Arthralgia—Docetaxel—lung cancer	0.000976	0.00174	CcSEcCtD
Apomorphine—Nausea—Vinorelbine—lung cancer	0.000975	0.00174	CcSEcCtD
Apomorphine—Asthenia—Irinotecan—lung cancer	0.000972	0.00174	CcSEcCtD
Apomorphine—Fatigue—Etoposide—lung cancer	0.000971	0.00173	CcSEcCtD
Apomorphine—Constipation—Etoposide—lung cancer	0.000963	0.00172	CcSEcCtD
Apomorphine—Fatigue—Paclitaxel—lung cancer	0.000952	0.0017	CcSEcCtD
Apomorphine—ADRA2A—bronchus—lung cancer	0.000952	0.0228	CbGeAlD
Apomorphine—Asthenia—Gemcitabine—lung cancer	0.000946	0.00169	CcSEcCtD
Apomorphine—Constipation—Paclitaxel—lung cancer	0.000944	0.00169	CcSEcCtD
Apomorphine—Confusional state—Docetaxel—lung cancer	0.000944	0.00169	CcSEcCtD
Apomorphine—Oedema—Docetaxel—lung cancer	0.000936	0.00167	CcSEcCtD
Apomorphine—Pruritus—Gemcitabine—lung cancer	0.000933	0.00167	CcSEcCtD
Apomorphine—Feeling abnormal—Etoposide—lung cancer	0.000928	0.00166	CcSEcCtD
Apomorphine—Diarrhoea—Irinotecan—lung cancer	0.000926	0.00166	CcSEcCtD
Apomorphine—Pneumonia—Doxorubicin—lung cancer	0.000921	0.00165	CcSEcCtD
Apomorphine—Shock—Docetaxel—lung cancer	0.000921	0.00165	CcSEcCtD
Apomorphine—Drowsiness—Doxorubicin—lung cancer	0.000916	0.00164	CcSEcCtD
Apomorphine—Feeling abnormal—Paclitaxel—lung cancer	0.00091	0.00163	CcSEcCtD
Apomorphine—Diarrhoea—Gemcitabine—lung cancer	0.000903	0.00161	CcSEcCtD
Apomorphine—Dizziness—Irinotecan—lung cancer	0.000895	0.0016	CcSEcCtD
Apomorphine—Urinary tract infection—Doxorubicin—lung cancer	0.00089	0.00159	CcSEcCtD
Apomorphine—Asthenia—Cisplatin—lung cancer	0.000882	0.00158	CcSEcCtD
Apomorphine—Hypotension—Docetaxel—lung cancer	0.000875	0.00156	CcSEcCtD
Apomorphine—Vomiting—Irinotecan—lung cancer	0.000861	0.00154	CcSEcCtD
Apomorphine—ADRA2A—trachea—lung cancer	0.000855	0.0205	CbGeAlD
Apomorphine—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000853	0.00152	CcSEcCtD
Apomorphine—Headache—Irinotecan—lung cancer	0.000848	0.00152	CcSEcCtD
Apomorphine—Insomnia—Docetaxel—lung cancer	0.000847	0.00151	CcSEcCtD
Apomorphine—Diarrhoea—Cisplatin—lung cancer	0.000841	0.0015	CcSEcCtD
Apomorphine—Vomiting—Gemcitabine—lung cancer	0.000839	0.0015	CcSEcCtD
Apomorphine—Dyspnoea—Docetaxel—lung cancer	0.000835	0.00149	CcSEcCtD
Apomorphine—Somnolence—Docetaxel—lung cancer	0.000832	0.00149	CcSEcCtD
Apomorphine—Mental disorder—Methotrexate—lung cancer	0.000832	0.00149	CcSEcCtD
Apomorphine—Headache—Gemcitabine—lung cancer	0.000826	0.00148	CcSEcCtD
Apomorphine—HTR2A—epithelium—lung cancer	0.000822	0.0197	CbGeAlD
Apomorphine—Asthenia—Etoposide—lung cancer	0.000808	0.00144	CcSEcCtD
Apomorphine—Fatigue—Docetaxel—lung cancer	0.000807	0.00144	CcSEcCtD
Apomorphine—Nausea—Irinotecan—lung cancer	0.000804	0.00144	CcSEcCtD
Apomorphine—ADRA2A—cardiac atrium—lung cancer	0.000803	0.0192	CbGeAlD
Apomorphine—Constipation—Docetaxel—lung cancer	0.0008	0.00143	CcSEcCtD
Apomorphine—Back pain—Methotrexate—lung cancer	0.0008	0.00143	CcSEcCtD
Apomorphine—Pruritus—Etoposide—lung cancer	0.000797	0.00142	CcSEcCtD
Apomorphine—Asthenia—Paclitaxel—lung cancer	0.000792	0.00142	CcSEcCtD
Apomorphine—DRD2—lung—lung cancer	0.000792	0.019	CbGeAlD
Apomorphine—Nausea—Gemcitabine—lung cancer	0.000783	0.0014	CcSEcCtD
Apomorphine—Vomiting—Cisplatin—lung cancer	0.000782	0.0014	CcSEcCtD
Apomorphine—Pruritus—Paclitaxel—lung cancer	0.000781	0.0014	CcSEcCtD
Apomorphine—Feeling abnormal—Docetaxel—lung cancer	0.000771	0.00138	CcSEcCtD
Apomorphine—Diarrhoea—Etoposide—lung cancer	0.000771	0.00138	CcSEcCtD
Apomorphine—ADRA2C—lung—lung cancer	0.00077	0.0184	CbGeAlD
Apomorphine—Flushing—Doxorubicin—lung cancer	0.000763	0.00136	CcSEcCtD
Apomorphine—Diarrhoea—Paclitaxel—lung cancer	0.000756	0.00135	CcSEcCtD
Apomorphine—Dizziness—Etoposide—lung cancer	0.000745	0.00133	CcSEcCtD
Apomorphine—Dizziness—Paclitaxel—lung cancer	0.00073	0.0013	CcSEcCtD
Apomorphine—Nausea—Cisplatin—lung cancer	0.00073	0.0013	CcSEcCtD
Apomorphine—HTR2A—trachea—lung cancer	0.000727	0.0174	CbGeAlD
Apomorphine—Mental disorder—Doxorubicin—lung cancer	0.00072	0.00129	CcSEcCtD
Apomorphine—Vomiting—Etoposide—lung cancer	0.000716	0.00128	CcSEcCtD
Apomorphine—Headache—Etoposide—lung cancer	0.000706	0.00126	CcSEcCtD
Apomorphine—Arthralgia—Methotrexate—lung cancer	0.000704	0.00126	CcSEcCtD
Apomorphine—Chest pain—Methotrexate—lung cancer	0.000704	0.00126	CcSEcCtD
Apomorphine—Vomiting—Paclitaxel—lung cancer	0.000702	0.00125	CcSEcCtD
Apomorphine—Back pain—Doxorubicin—lung cancer	0.000692	0.00124	CcSEcCtD
Apomorphine—Headache—Paclitaxel—lung cancer	0.000692	0.00124	CcSEcCtD
Apomorphine—Confusional state—Methotrexate—lung cancer	0.00068	0.00122	CcSEcCtD
Apomorphine—Asthenia—Docetaxel—lung cancer	0.000672	0.0012	CcSEcCtD
Apomorphine—Nausea—Etoposide—lung cancer	0.000669	0.0012	CcSEcCtD
Apomorphine—HTR2B—lymph node—lung cancer	0.000669	0.016	CbGeAlD
Apomorphine—Pruritus—Docetaxel—lung cancer	0.000662	0.00118	CcSEcCtD
Apomorphine—Nausea—Paclitaxel—lung cancer	0.000656	0.00117	CcSEcCtD
Apomorphine—Hyperhidrosis—Methotrexate—lung cancer	0.000652	0.00117	CcSEcCtD
Apomorphine—Syncope—Doxorubicin—lung cancer	0.000642	0.00115	CcSEcCtD
Apomorphine—Diarrhoea—Docetaxel—lung cancer	0.00064	0.00114	CcSEcCtD
Apomorphine—Hypotension—Methotrexate—lung cancer	0.00063	0.00113	CcSEcCtD
Apomorphine—Loss of consciousness—Doxorubicin—lung cancer	0.000629	0.00112	CcSEcCtD
Apomorphine—Dizziness—Docetaxel—lung cancer	0.000619	0.00111	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000615	0.0011	CcSEcCtD
Apomorphine—ADRA2A—lung—lung cancer	0.000614	0.0147	CbGeAlD
Apomorphine—Insomnia—Methotrexate—lung cancer	0.00061	0.00109	CcSEcCtD
Apomorphine—Arthralgia—Doxorubicin—lung cancer	0.000609	0.00109	CcSEcCtD
Apomorphine—Chest pain—Doxorubicin—lung cancer	0.000609	0.00109	CcSEcCtD
Apomorphine—Anxiety—Doxorubicin—lung cancer	0.000607	0.00108	CcSEcCtD
Apomorphine—Dyspnoea—Methotrexate—lung cancer	0.000601	0.00107	CcSEcCtD
Apomorphine—Somnolence—Methotrexate—lung cancer	0.0006	0.00107	CcSEcCtD
Apomorphine—Vomiting—Docetaxel—lung cancer	0.000595	0.00106	CcSEcCtD
Apomorphine—Confusional state—Doxorubicin—lung cancer	0.000589	0.00105	CcSEcCtD
Apomorphine—Headache—Docetaxel—lung cancer	0.000586	0.00105	CcSEcCtD
Apomorphine—Oedema—Doxorubicin—lung cancer	0.000584	0.00104	CcSEcCtD
Apomorphine—Fatigue—Methotrexate—lung cancer	0.000582	0.00104	CcSEcCtD
Apomorphine—Shock—Doxorubicin—lung cancer	0.000575	0.00103	CcSEcCtD
Apomorphine—Hyperhidrosis—Doxorubicin—lung cancer	0.000565	0.00101	CcSEcCtD
Apomorphine—Nausea—Docetaxel—lung cancer	0.000556	0.000993	CcSEcCtD
Apomorphine—Feeling abnormal—Methotrexate—lung cancer	0.000556	0.000993	CcSEcCtD
Apomorphine—Hypotension—Doxorubicin—lung cancer	0.000546	0.000975	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000532	0.000951	CcSEcCtD
Apomorphine—Insomnia—Doxorubicin—lung cancer	0.000528	0.000944	CcSEcCtD
Apomorphine—ADRA2C—lymph node—lung cancer	0.000526	0.0126	CbGeAlD
Apomorphine—HTR2A—lung—lung cancer	0.000522	0.0125	CbGeAlD
Apomorphine—Dyspnoea—Doxorubicin—lung cancer	0.000521	0.00093	CcSEcCtD
Apomorphine—Somnolence—Doxorubicin—lung cancer	0.000519	0.000928	CcSEcCtD
Apomorphine—Fatigue—Doxorubicin—lung cancer	0.000504	0.0009	CcSEcCtD
Apomorphine—Constipation—Doxorubicin—lung cancer	0.0005	0.000892	CcSEcCtD
Apomorphine—Asthenia—Methotrexate—lung cancer	0.000484	0.000865	CcSEcCtD
Apomorphine—Feeling abnormal—Doxorubicin—lung cancer	0.000481	0.00086	CcSEcCtD
Apomorphine—Pruritus—Methotrexate—lung cancer	0.000477	0.000853	CcSEcCtD
Apomorphine—Diarrhoea—Methotrexate—lung cancer	0.000462	0.000825	CcSEcCtD
Apomorphine—Dizziness—Methotrexate—lung cancer	0.000446	0.000797	CcSEcCtD
Apomorphine—Vomiting—Methotrexate—lung cancer	0.000429	0.000766	CcSEcCtD
Apomorphine—Headache—Methotrexate—lung cancer	0.000423	0.000755	CcSEcCtD
Apomorphine—ADRA2A—lymph node—lung cancer	0.00042	0.0101	CbGeAlD
Apomorphine—Asthenia—Doxorubicin—lung cancer	0.000419	0.000749	CcSEcCtD
Apomorphine—Pruritus—Doxorubicin—lung cancer	0.000413	0.000738	CcSEcCtD
Apomorphine—Nausea—Methotrexate—lung cancer	0.000401	0.000716	CcSEcCtD
Apomorphine—Diarrhoea—Doxorubicin—lung cancer	0.0004	0.000714	CcSEcCtD
Apomorphine—Dizziness—Doxorubicin—lung cancer	0.000386	0.00069	CcSEcCtD
Apomorphine—Vomiting—Doxorubicin—lung cancer	0.000371	0.000664	CcSEcCtD
Apomorphine—Headache—Doxorubicin—lung cancer	0.000366	0.000654	CcSEcCtD
Apomorphine—Nausea—Doxorubicin—lung cancer	0.000347	0.00062	CcSEcCtD
Apomorphine—ADRA1D—Signaling Pathways—STAT3—lung cancer	1.98e-05	4.98e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—STAT3—lung cancer	1.98e-05	4.98e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—MYC—lung cancer	1.98e-05	4.97e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—RAF1—lung cancer	1.98e-05	4.97e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—NRAS—lung cancer	1.98e-05	4.97e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—NRAS—lung cancer	1.98e-05	4.97e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling by GPCR—IL6—lung cancer	1.98e-05	4.96e-05	CbGpPWpGaD
Apomorphine—ADRA1B—GPCR downstream signaling—AKT1—lung cancer	1.98e-05	4.96e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—KRAS—lung cancer	1.98e-05	4.96e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—MTOR—lung cancer	1.96e-05	4.93e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—PIK3CB—lung cancer	1.96e-05	4.93e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—CASP3—lung cancer	1.96e-05	4.92e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—ERBB2—lung cancer	1.96e-05	4.92e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—IL2—lung cancer	1.96e-05	4.91e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling by GPCR—AKT1—lung cancer	1.95e-05	4.9e-05	CbGpPWpGaD
Apomorphine—DRD5—Signaling Pathways—AKT1—lung cancer	1.95e-05	4.89e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—KRAS—lung cancer	1.95e-05	4.89e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling by GPCR—IL6—lung cancer	1.95e-05	4.89e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—MMP9—lung cancer	1.94e-05	4.88e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—CCND1—lung cancer	1.94e-05	4.86e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—EGFR—lung cancer	1.94e-05	4.86e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—CDKN1A—lung cancer	1.94e-05	4.86e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—MMP9—lung cancer	1.93e-05	4.86e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—JUN—lung cancer	1.93e-05	4.85e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—PTEN—lung cancer	1.93e-05	4.85e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—MTOR—lung cancer	1.93e-05	4.85e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—PIK3CB—lung cancer	1.93e-05	4.85e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—CDKN1A—lung cancer	1.93e-05	4.84e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—PTEN—lung cancer	1.92e-05	4.83e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—MAPK3—lung cancer	1.92e-05	4.82e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—KRAS—lung cancer	1.92e-05	4.81e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—EP300—lung cancer	1.91e-05	4.79e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—CCND1—lung cancer	1.91e-05	4.79e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—JUN—lung cancer	1.9e-05	4.78e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—MAPK3—lung cancer	1.9e-05	4.76e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—MAPK3—lung cancer	1.9e-05	4.76e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CXCL8—lung cancer	1.89e-05	4.74e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling by GPCR—AKT1—lung cancer	1.89e-05	4.73e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—MMP9—lung cancer	1.88e-05	4.72e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling by GPCR—AKT1—lung cancer	1.88e-05	4.71e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—HRAS—lung cancer	1.88e-05	4.71e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—CDKN1A—lung cancer	1.87e-05	4.71e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—PTEN—lung cancer	1.87e-05	4.69e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—MYC—lung cancer	1.87e-05	4.69e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CXCL8—lung cancer	1.86e-05	4.66e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—SRC—lung cancer	1.86e-05	4.66e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—MMP9—lung cancer	1.85e-05	4.65e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—HRAS—lung cancer	1.85e-05	4.63e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—CDKN1A—lung cancer	1.85e-05	4.63e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—EP300—lung cancer	1.84e-05	4.63e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—MYC—lung cancer	1.84e-05	4.63e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—MYC—lung cancer	1.84e-05	4.63e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—PTEN—lung cancer	1.84e-05	4.62e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—EP300—lung cancer	1.83e-05	4.6e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—KRAS—lung cancer	1.83e-05	4.59e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—PIK3CA—lung cancer	1.83e-05	4.59e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—EGFR—lung cancer	1.83e-05	4.59e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling by GPCR—AKT1—lung cancer	1.83e-05	4.58e-05	CbGpPWpGaD
Apomorphine—DRD2—GPCR downstream signaling—AKT1—lung cancer	1.82e-05	4.58e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—PTEN—lung cancer	1.82e-05	4.56e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—PIK3CA—lung cancer	1.81e-05	4.55e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—VEGFA—lung cancer	1.81e-05	4.54e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MDM2—lung cancer	1.81e-05	4.54e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CASP3—lung cancer	1.81e-05	4.53e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—IL2—lung cancer	1.8e-05	4.53e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—EGFR—lung cancer	1.8e-05	4.52e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—EGFR—lung cancer	1.8e-05	4.52e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—RAF1—lung cancer	1.8e-05	4.52e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling by GPCR—AKT1—lung cancer	1.8e-05	4.51e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—IL6—lung cancer	1.8e-05	4.5e-05	CbGpPWpGaD
Apomorphine—HTR2A—GPCR downstream signaling—AKT1—lung cancer	1.79e-05	4.5e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—SRC—lung cancer	1.79e-05	4.5e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—STAT3—lung cancer	1.79e-05	4.49e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—PIK3CA—lung cancer	1.79e-05	4.49e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—NRAS—lung cancer	1.79e-05	4.48e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—EP300—lung cancer	1.78e-05	4.48e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—SRC—lung cancer	1.78e-05	4.48e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—ERBB2—lung cancer	1.78e-05	4.47e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CASP3—lung cancer	1.78e-05	4.46e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—IL2—lung cancer	1.78e-05	4.45e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—TP53—lung cancer	1.77e-05	4.44e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—IL6—lung cancer	1.77e-05	4.43e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—PIK3CA—lung cancer	1.76e-05	4.42e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CCND1—lung cancer	1.76e-05	4.41e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MTOR—lung cancer	1.76e-05	4.41e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	1.76e-05	4.41e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—EP300—lung cancer	1.76e-05	4.41e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—JUN—lung cancer	1.75e-05	4.4e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—VEGFA—lung cancer	1.75e-05	4.38e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—VEGFA—lung cancer	1.74e-05	4.36e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—SRC—lung cancer	1.73e-05	4.35e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—EP300—lung cancer	1.73e-05	4.35e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—TP53—lung cancer	1.73e-05	4.35e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CCND1—lung cancer	1.73e-05	4.34e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—STAT3—lung cancer	1.73e-05	4.34e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—JUN—lung cancer	1.73e-05	4.33e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—KRAS—lung cancer	1.73e-05	4.33e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—NRAS—lung cancer	1.72e-05	4.33e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—STAT3—lung cancer	1.72e-05	4.32e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—NRAS—lung cancer	1.72e-05	4.31e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—MAPK3—lung cancer	1.71e-05	4.29e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—SRC—lung cancer	1.71e-05	4.28e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—MMP9—lung cancer	1.71e-05	4.28e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—TP53—lung cancer	1.7e-05	4.28e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—KRAS—lung cancer	1.7e-05	4.27e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—KRAS—lung cancer	1.7e-05	4.27e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CDKN1A—lung cancer	1.7e-05	4.27e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—PTEN—lung cancer	1.7e-05	4.26e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—HRAS—lung cancer	1.69e-05	4.25e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CXCL8—lung cancer	1.69e-05	4.24e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—VEGFA—lung cancer	1.69e-05	4.24e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—PIK3CA—lung cancer	1.68e-05	4.22e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—MMP9—lung cancer	1.68e-05	4.22e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—HRAS—lung cancer	1.68e-05	4.21e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CDKN1A—lung cancer	1.67e-05	4.2e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—STAT3—lung cancer	1.67e-05	4.2e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—PTEN—lung cancer	1.67e-05	4.19e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—NRAS—lung cancer	1.67e-05	4.19e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—MYC—lung cancer	1.66e-05	4.18e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—VEGFA—lung cancer	1.66e-05	4.17e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—HRAS—lung cancer	1.66e-05	4.16e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—AKT1—lung cancer	1.66e-05	4.16e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—MAPK3—lung cancer	1.65e-05	4.15e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—STAT3—lung cancer	1.65e-05	4.13e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—MAPK3—lung cancer	1.64e-05	4.12e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—NRAS—lung cancer	1.64e-05	4.12e-05	CbGpPWpGaD
Apomorphine—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	1.63e-05	4.1e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—HRAS—lung cancer	1.63e-05	4.09e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—AKT1—lung cancer	1.63e-05	4.09e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—EGFR—lung cancer	1.63e-05	4.09e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—TP53—lung cancer	1.63e-05	4.08e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—IL6—lung cancer	1.62e-05	4.06e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—EP300—lung cancer	1.62e-05	4.06e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CASP3—lung cancer	1.62e-05	4.06e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—IL2—lung cancer	1.61e-05	4.05e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—IL6—lung cancer	1.61e-05	4.03e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—MYC—lung cancer	1.61e-05	4.03e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—MAPK3—lung cancer	1.6e-05	4.01e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—MYC—lung cancer	1.6e-05	4.01e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—EP300—lung cancer	1.59e-05	4e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—PIK3CA—lung cancer	1.59e-05	3.98e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—IL6—lung cancer	1.59e-05	3.98e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Metabolism—PIK3CA—lung cancer	1.58e-05	3.96e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CCND1—lung cancer	1.57e-05	3.95e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—SRC—lung cancer	1.57e-05	3.95e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—MAPK3—lung cancer	1.57e-05	3.95e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—EGFR—lung cancer	1.57e-05	3.94e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—JUN—lung cancer	1.57e-05	3.94e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—PIK3CA—lung cancer	1.56e-05	3.93e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—PIK3CA—lung cancer	1.56e-05	3.93e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—EGFR—lung cancer	1.56e-05	3.92e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—IL6—lung cancer	1.56e-05	3.92e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—HRAS—lung cancer	1.56e-05	3.9e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—MYC—lung cancer	1.55e-05	3.9e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—SRC—lung cancer	1.55e-05	3.89e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—KRAS—lung cancer	1.54e-05	3.86e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—TP53—lung cancer	1.53e-05	3.85e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—VEGFA—lung cancer	1.53e-05	3.85e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—MYC—lung cancer	1.53e-05	3.84e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MMP9—lung cancer	1.53e-05	3.84e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	1.52e-05	3.82e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—EGFR—lung cancer	1.52e-05	3.82e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PTEN—lung cancer	1.52e-05	3.81e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—STAT3—lung cancer	1.52e-05	3.81e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—NRAS—lung cancer	1.51e-05	3.8e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—TP53—lung cancer	1.51e-05	3.8e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—TP53—lung cancer	1.51e-05	3.8e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—VEGFA—lung cancer	1.51e-05	3.79e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—EGFR—lung cancer	1.5e-05	3.76e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—STAT3—lung cancer	1.49e-05	3.75e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—AKT1—lung cancer	1.49e-05	3.75e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—NRAS—lung cancer	1.49e-05	3.74e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—IL6—lung cancer	1.49e-05	3.74e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—KRAS—lung cancer	1.48e-05	3.73e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—AKT1—lung cancer	1.48e-05	3.72e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—KRAS—lung cancer	1.48e-05	3.71e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—HRAS—lung cancer	1.47e-05	3.68e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—AKT1—lung cancer	1.46e-05	3.67e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—MAPK3—lung cancer	1.45e-05	3.64e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—EP300—lung cancer	1.45e-05	3.64e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—HRAS—lung cancer	1.45e-05	3.63e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—HRAS—lung cancer	1.45e-05	3.63e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—AKT1—lung cancer	1.44e-05	3.61e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—KRAS—lung cancer	1.44e-05	3.6e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—MAPK3—lung cancer	1.43e-05	3.58e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—KRAS—lung cancer	1.41e-05	3.55e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—PIK3CA—lung cancer	1.41e-05	3.55e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—MYC—lung cancer	1.41e-05	3.54e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—SRC—lung cancer	1.41e-05	3.54e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—IL6—lung cancer	1.4e-05	3.52e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—MYC—lung cancer	1.39e-05	3.48e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—IL6—lung cancer	1.39e-05	3.48e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—IL6—lung cancer	1.39e-05	3.48e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—EGFR—lung cancer	1.38e-05	3.46e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—AKT1—lung cancer	1.37e-05	3.45e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—VEGFA—lung cancer	1.37e-05	3.44e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—TP53—lung cancer	1.37e-05	3.43e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—PIK3CA—lung cancer	1.36e-05	3.42e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—STAT3—lung cancer	1.36e-05	3.41e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—EGFR—lung cancer	1.36e-05	3.41e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—PIK3CA—lung cancer	1.36e-05	3.41e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—NRAS—lung cancer	1.36e-05	3.4e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—PIK3CA—lung cancer	1.32e-05	3.31e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—TP53—lung cancer	1.32e-05	3.31e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—TP53—lung cancer	1.31e-05	3.29e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—HRAS—lung cancer	1.31e-05	3.28e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—KRAS—lung cancer	1.3e-05	3.27e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—PIK3CA—lung cancer	1.3e-05	3.26e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MAPK3—lung cancer	1.3e-05	3.26e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—AKT1—lung cancer	1.3e-05	3.25e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Metabolism—AKT1—lung cancer	1.29e-05	3.24e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—KRAS—lung cancer	1.28e-05	3.22e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—PIK3CA—lung cancer	1.28e-05	3.22e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—AKT1—lung cancer	1.28e-05	3.21e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—AKT1—lung cancer	1.28e-05	3.21e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—TP53—lung cancer	1.28e-05	3.2e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MYC—lung cancer	1.26e-05	3.17e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—HRAS—lung cancer	1.26e-05	3.17e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—TP53—lung cancer	1.26e-05	3.15e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—HRAS—lung cancer	1.26e-05	3.15e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—IL6—lung cancer	1.25e-05	3.14e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—EGFR—lung cancer	1.24e-05	3.1e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—HRAS—lung cancer	1.22e-05	3.06e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—IL6—lung cancer	1.21e-05	3.03e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—HRAS—lung cancer	1.2e-05	3.02e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—IL6—lung cancer	1.2e-05	3.02e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—PIK3CA—lung cancer	1.2e-05	3.01e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—PIK3CA—lung cancer	1.18e-05	2.96e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—IL6—lung cancer	1.17e-05	2.93e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—KRAS—lung cancer	1.17e-05	2.93e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—TP53—lung cancer	1.16e-05	2.91e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—AKT1—lung cancer	1.15e-05	2.9e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—IL6—lung cancer	1.15e-05	2.89e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—TP53—lung cancer	1.14e-05	2.86e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—AKT1—lung cancer	1.11e-05	2.8e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—AKT1—lung cancer	1.11e-05	2.78e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—HRAS—lung cancer	1.11e-05	2.78e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—HRAS—lung cancer	1.09e-05	2.74e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—AKT1—lung cancer	1.08e-05	2.71e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	1.07e-05	2.69e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—AKT1—lung cancer	1.06e-05	2.66e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—IL6—lung cancer	1.06e-05	2.66e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—AKT1—lung cancer	1.05e-05	2.63e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—IL6—lung cancer	1.04e-05	2.62e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—TP53—lung cancer	1.04e-05	2.6e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—HRAS—lung cancer	9.92e-06	2.49e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—AKT1—lung cancer	9.78e-06	2.45e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—AKT1—lung cancer	9.63e-06	2.42e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—IL6—lung cancer	9.49e-06	2.38e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—AKT1—lung cancer	8.76e-06	2.2e-05	CbGpPWpGaD
